FAPI PET Scan in Delhi — Advanced Cancer Detection & Tumor Imaging | Neurad Diagnostics

Cancer diagnosis is entering a new era, and at the forefront of this transformation is the FAPI PET Scan. If your oncologist has recommended this advanced imaging study, or if you want to understand all your diagnostic options, this guide provides comprehensive information about the 68Ga-FAPI PET/CT scan available at Neurad Diagnostics in Delhi. The this scan is rapidly emerging as one of the most powerful tools in oncologic imaging, offering a completely new way to visualize cancer that complements — and in many cases surpasses — conventional FDG PET scanning.

According to clinical research published in the Journal of Nuclear Medicine, 68Ga-FAPI PET demonstrates superior tumor-to-background contrast compared to FDG PET in multiple cancer types including gastric, pancreatic, and biliary cancers. The European Association of Nuclear Medicine (EANM) recognizes FAPI imaging as a promising advancement in oncologic molecular imaging.

What Is a the FAPI scan?

The this PET/CT, formally known as 68Ga-FAPI PET/CT, is a cutting-edge nuclear medicine imaging study that uses a Gallium-68 labelled tracer called Fibroblast Activation Protein Inhibitor (FAPI). This tracer targets Fibroblast Activation Protein (FAP) — an enzyme that is massively overexpressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a wide variety of solid cancers. FAP is expressed at extremely low levels in normal healthy tissues, which gives the FAPI PET Scan exceptionally high tumor-to-background contrast — making tumors stand out brightly against a very clean background image.

What makes FAPI unique is that it does not target the cancer cells directly but rather the reactive stromal cells that surround and support tumors. This is a completely different biological target from FDG (which measures glucose metabolism) or PSMA (which targets prostate cancer cells). As a result, the procedure can detect cancers that are FDG-negative, and can image tumors in locations with high background FDG activity (like the brain, liver, stomach, and inflamed tissues) with far superior clarity. Neurad Diagnostics is among the pioneering centers in Delhi NCR offering this next-generation diagnostic technology.

Why Doctors Recommend the this scan

Oncologists, radiation oncologists, and surgical oncologists recommend FAPI PET Scan in situations where conventional imaging fails or provides suboptimal information. Key clinical indications include:

For cancers with low FDG avidity — such as mucinous tumors, well-differentiated carcinomas, or hepatocellular carcinoma — FAPI PET often detects disease that a standard FDG PET scan would miss entirely. For tumors in the liver, brain, or peritoneum where high normal tissue FDG uptake obscures lesions, FAPI’s very low background signal provides dramatically better visualization. For radiotherapy treatment planning, FAPI PET precisely delineates the extent of the tumor microenvironment, allowing more accurate target volume definition. And for patients being evaluated for FAP-targeted radionuclide therapy — an emerging treatment approach — FAPI PET confirms receptor expression and treatment eligibility.

Cancers and Diseases Detected by this imaging test

The the FAPI scan is effective across a remarkable range of solid tumors due to the near-universal overexpression of FAP in cancer-associated fibroblasts. High-performance cancers for FAPI imaging include:

• Gastric Cancer (Stomach Cancer): Among the highest FAP expression — FAPI PET shows exceptional performance
• Cholangiocarcinoma (Bile Duct Cancer): Very high FAP expression makes FAPI superior to FDG in many cases
• Pancreatic Ductal Adenocarcinoma: FAPI PET often outperforms FDG PET for this difficult-to-image cancer
• Lung Cancer: Both adenocarcinoma and squamous cell carcinoma show high FAPI uptake
• Breast Cancer: Particularly useful in lobular breast cancer where FDG uptake can be low
• Ovarian Cancer: High tumor-to-background contrast for peritoneal disease assessment
• Colorectal Cancer: Effective for staging and recurrence detection
• Head and Neck Cancers
• Esophageal Cancer
• Hepatocellular Carcinoma (HCC)
• Sarcomas: High FAP expression in many subtypes
• Thyroid Cancer
• Carcinoma of Unknown Primary: FAPI PET can detect the primary tumor site missed by FDG

Who Needs a FAPI PET Scan?

Your doctor may recommend a this PET/CT in Delhi in these clinical scenarios:

• FDG PET Scan was inconclusive or negative despite strong clinical suspicion of cancer
• Initial staging of cancers known to have high FAP expression (gastric, pancreatic, cholangiocarcinoma)
• Assessment of peritoneal carcinomatosis extent
• Radiotherapy treatment planning requiring precise tumor volume delineation
• Evaluation of cancer recurrence after treatment
• Carcinoma of unknown primary (CUP syndrome)
• Assessment of metastatic disease extent in complex anatomical regions (liver, brain)
• Evaluation for FAP-targeted radionuclide therapy eligibility
• Situations where inflammation confounds FDG PET interpretation

Symptoms That May Lead to the procedure

• Unexplained abdominal pain or discomfort
• Unintentional significant weight loss
• Loss of appetite or early satiety
• Jaundice (yellow skin/eyes — suggestive of liver or bile duct pathology)
• Persistent cough or chest pain
• Abnormal tumour marker elevation (CA 19-9, CEA, AFP)
• Suspicious findings on CT or MRI requiring further characterization
• Fatigue and weakness not explained by other causes
• Palpable lymph node enlargement

How the FAPI PET Scan Procedure Works

The this scan works through a fundamentally different biological mechanism than FDG or PSMA PET. The Gallium-68 labelled FAPI tracer is designed to bind specifically and with high affinity to Fibroblast Activation Protein alpha (FAP-α) — an enzyme found at very high levels in cancer-associated fibroblasts (CAFs) in the tumor microenvironment and at negligible levels in most normal adult tissues.

One of the major clinical advantages of FAPI is its extremely rapid uptake and clearance kinetics. Unlike FDG which requires 60 minutes of uptake and shows high background in liver and brain, FAPI achieves maximum tumor-to-background ratio within just 10–30 minutes post-injection. This results in exceptionally clean images with tumor sites showing intense signal against a very low background — making even small tumors and metastases clearly visible. The combined PET/CT acquisition provides both the functional tumor map and anatomical context simultaneously.

Preparation Before the this imaging test

One of the advantages of the FAPI PET Scan is that it generally does not require strict fasting (unlike FDG PET). However, at Neurad Diagnostics in Delhi, we provide specific preparation instructions based on your individual clinical situation:

• Fasting: Light meals or fasting per physician instructions (usually not strict 6-hour fasting required)
• Medications: Continue all regular medications unless specifically told otherwise
• Hydration: Drink adequate fluids before and after the scan
• Prior imaging and records: Bring all previous CT, MRI, PET reports and tumour marker results
• Clothing: Comfortable loose-fitting clothing without metal fasteners
• Inform about: Any recent surgery, active infections, or inflammatory conditions

Step-by-Step the FAPI scan Procedure at Neurad Diagnostics

1. Registration and clinical review: Our nuclear medicine team reviews your case history and imaging records.
2. IV cannula placement: A small IV line is placed for tracer injection.
3. 68Ga-FAPI tracer injection: The tracer is administered intravenously — a quick, painless process.
4. Rapid uptake period: Due to FAPI’s fast kinetics, uptake time is typically only 10–30 minutes — significantly shorter than FDG PET.
5. PET/CT scan acquisition: Whole-body PET/CT images are acquired in approximately 20–30 minutes.
6. Post-scan care: You may eat, drink, and resume activities immediately after the scan.
7. Expert reporting: Our nuclear medicine physicians analyze the images and prepare a detailed clinical report.

Advantages of this PET/CT Technology

• Very high tumor-to-background contrast: Exceptional image quality with minimal background noise
• Low liver and brain background: Detects hepatic and brain lesions missed by FDG
• No strict fasting required: More convenient for patients
• Rapid uptake kinetics: Shorter total procedure time than FDG PET
• Pan-cancer applicability: Works across a very wide range of solid tumors
• Detects FDG-negative tumors: Fills critical diagnostic gap
• Superior peritoneal disease assessment
• Radiotherapy planning precision
• FAP-targeted therapy eligibility assessment

Accuracy and Clinical Benefits

Clinical research on FAPI PET Scan is rapidly accumulating and consistently demonstrates superior or complementary performance to FDG PET in multiple cancer types. A comprehensive study published in the Journal of Nuclear Medicine evaluating 80 patients with 28 different cancer types found that FAPI PET had higher tumor uptake than FDG in 28 of 28 cancer entities, with tumor-to-liver ratios up to 30-fold higher than FDG for some cancers like cholangiocarcinoma and gastric cancer. For peritoneal carcinomatosis specifically, FAPI PET has been shown to detect disease in 75-90% of patients compared to 40-60% with CT alone.

In the Indian clinical setting, where many patients with gastrointestinal cancers, pancreatic cancer, and cholangiocarcinoma present with diagnostic challenges, the procedure at Neurad Diagnostics in Delhi offers a decisive diagnostic advantage that can directly influence surgical resectability assessment, radiotherapy planning, and systemic treatment decisions.

Safety Information

The this scan is very safe:

• Low radiation dose: Effective dose of approximately 3–5 mSv — well within acceptable diagnostic imaging limits
• Short Ga-68 half-life: Radioactivity clears from the body within hours
• No iodine contrast: No contrast allergy or kidney risks
• Excellent tolerability: No significant adverse effects reported in clinical studies
• AERB-regulated facility: All procedures at Neurad Diagnostics comply with Indian radiation safety standards

Cost of FAPI PET Scan in Delhi NCR

The cost of this imaging test in Delhi reflects the advanced Gallium-68 technology, specialized tracer preparation, and expert nuclear medicine interpretation required. At Neurad Diagnostics, we are committed to transparent, competitive pricing for the FAPI scan in Delhi NCR. Please contact us directly for current pricing information. Given the level of clinical information this scan provides — potentially replacing multiple investigations and directly guiding treatment — it represents excellent clinical and economic value.

Why Choose Neurad Diagnostics for FAPI PET Scan in Delhi?

Neurad Diagnostics is a pioneer in advanced Gallium-68 molecular imaging in Delhi NCR. We offer the full range of Gallium-68 tracers including FAPI, DOTANOC, PSMA, Exendin, and Trivehexin — making us a uniquely comprehensive molecular imaging center. Our nuclear medicine specialists stay at the forefront of clinical research in FAP-targeted imaging and therapy, ensuring that every patient benefits from the most current and accurate diagnostic approach. We serve patients from across Delhi, Noida, Gurgaon, Faridabad, Ghaziabad, and all of India, combining world-class technology with personalized, compassionate care.

Frequently Asked Questions About this PET/CT

1. What does FAPI stand for?

FAPI stands for Fibroblast Activation Protein Inhibitor — the ligand used to target Fibroblast Activation Protein alpha (FAP-α), which is overexpressed by cancer-associated fibroblasts in most solid tumors.

2. Is FAPI PET better than FDG PET?

For many cancer types — particularly gastric, pancreatic, biliary, and peritoneal cancers — FAPI PET shows superior tumor-to-background contrast. The two tests complement each other and some patients may benefit from both. Your oncologist will determine which is most appropriate.

3. Do I need to fast for the procedure?

Unlike FDG PET Scan, FAPI PET generally does not require strict fasting. This makes it more convenient for patients, particularly diabetics or those who find fasting difficult. Follow your physician’s specific instructions.

4. Can FAPI PET detect peritoneal metastases?

Yes. FAPI PET Scan has shown particularly good performance for detecting peritoneal carcinomatosis, often identifying implants that CT and FDG PET miss due to their small size or FDG-negative nature.

5. Is FAPI PET used for treatment planning?

Yes. The high tumor-to-background contrast of FAPI PET makes it highly valuable for radiotherapy target volume delineation. It helps radiation oncologists define the true extent of disease more accurately than CT or FDG PET alone.

6. Can normal tissues show FAPI uptake?

FAP is minimally expressed in normal adult tissues. Some physiological FAPI uptake can be seen in the uterus, bone marrow, and sites of inflammation or fibrosis. Your nuclear medicine physician will account for these in interpreting your scan.

7. How is FAPI PET different from DOTANOC PET?

DOTANOC PET targets somatostatin receptors on neuroendocrine tumor cells and is used specifically for NETs. FAPI PET targets FAP on cancer-associated fibroblasts and is applicable to a much broader range of solid tumors including carcinomas and sarcomas.

8. Where can I get this scan in Delhi?

Neurad Diagnostics offers this imaging test in Delhi NCR. Contact us to schedule your appointment. We serve patients from across Delhi, NCR, and India.

9. Is FAPI PET Scan approved for routine use?

68Ga-FAPI is an investigational/emerging tracer that has shown excellent results in extensive clinical research. Its use is expanding rapidly in leading cancer centers globally. Neurad Diagnostics offers it as part of its advanced molecular imaging portfolio.

10. Can the FAPI scan detect cancer recurrence?

Yes. this PET/CT is used for detecting cancer recurrence after surgery or other treatments, particularly in cases where FDG PET is inconclusive or where the cancer type is known to have low FDG avidity.

Conclusion — Book Your FAPI PET Scan at Neurad Diagnostics Delhi

The the procedure represents the frontier of oncologic molecular imaging. Its unique ability to detect cancer through the tumor microenvironment, rather than the cancer cells themselves, opens new possibilities for diagnosing cancers that conventional imaging misses. If your oncologist has recommended this scan, or if conventional imaging has not provided clear answers about a suspected cancer, the this scan at Neurad Diagnostics in Delhi may be the diagnostic breakthrough you need.